[1] Bhati CS, Bhatt AN, Starkey G, et al. Acute liver failure due to primary angiosarcoma: a case report and review of literature. World J Surg Oncol, 2008,6:104.
[2] Kumar A, Sharma B, Samant H. Liver angiosarcoma//Treasure Island (FL),2023:125-127.
[3] Singh G, Mills C, Asadi K, et al. Hepatic angiosarcoma as a cause of acute liver failure. BMJ Case Rep, 2012,2012:bcr2012006417.
[4] Lazăr DC, Avram MF, Romoan I, et al. Malignant hepatic vascular tumors in adults: Characteristics, diagnostic difficulties and current management.World J Clin Oncol, 2019,10(3):110-135.
[5] Yasir S, Torbenson MS. Angiosarcoma of the liver: Clinicopathologic features and morphologic patterns. Am J Surg Pathol, 2019,43(5):581-590.
[6] Rosen EA, Vallurupalli M, Choy E, et al. Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma: A case report. Medicine (Baltimore), 2018,97(47):e13321.
[7] Ito Z, Kajihara M, Kobayashi Y, et al. Hepatic angiosarcoma associated with esophageal variceal hemorrhage. Case Rep Gastroenterol, 2016,10(2): 440 -445.
[8] Enweluzo C, Chaudry D, Philip JK, et al. Hepatic angiosarcoma: An unusual case of intractable gastrointestinal bleeding. Gastroenterol Res, 2013,6(2):74-76.
[9] Zheng YW, Zhang XW, Zhang JL, et al. Primary hepatic angiosarcoma and potential treatment options. J Gastroenterol Hepatol, 2014,29 (5):906-911.
[10] Yi LL, Zhang JX, Zhou SG, et al. CT and MRI studies of hepatic angiosarcoma. Clin Radiol, 2019,74(5):406,e1-406,e8.
[11] Gaballah AH, Jensen CT, Palmquist S, et al. Angiosarcoma: clinical and imaging features from head to toe. Br J Radiol,2017,90 (1075):20170039.
[12] 张伟,王兰荣,薛鹏等.原发性肝血管肉瘤的CT和MRI表现. 临床放射学杂志,2014,33(5): 734-738.
[13] Zen Y, Sofue K. Sinusoidal-type angiosarcoma of the liver: Imaging features and potential diagnostic utility of p53 immunostaining. Am J Surg Pathol, 2019,43(12):1728-1731.
[14] Vij M, Patil V, Hakeem A, et al. Sinusoidal hepatic angiosarcoma on a background of non-cirrhotic portal hypertension and nodular regenerative hyperplasia masquerading as acute on chronic liver failure. J Gastrointest Cancer, 2021,52(2):766-770.
[15] Pickhardt PJ, Kitchin D, Lubner MG, et al. Primary hepatic angiosarcoma: multi-institutional comprehensive cancer centre review of multiphasic CT and MR imaging in 35 patients. Eur Radiol,2015,25 (2):315-322.
[16] Ogawa M, Ae R, Sasahara T. Primary hepatic angiosarcoma: A case report with 10-year patient medical data. Case Rep Oncol, 2017,10(3):851-856.
[17] Zeng D, Cheng J, Gong Z, et al. A pooled analysis of primary hepatic angiosarcoma. Jpn J Clin Oncol, 2020,50(5):556-567.
[18] Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol, 2008,26(32):5269-5274.
[19] Qiao Y, Yang J, Liu L, et al. Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report. BMC Cancer, 2018,18(1):212.
[20] Miettinen M, Rikala MS, Rys J, et al. Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am J Surg Pathol,2012,36 (4):629-639.
[21] Jiang L, Xie L, Li G, et al. Clinical characteristics and surgical treatments of primary hepatic angiosarcoma. BMC Gastroenterol, 2021,21(1):156. |
